Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.33 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8125843 | 0.83 | KMT2A (0.40) | KMT2AGAANFE2L2MAOBALDH1A1 | |
| SCHEMBL4634623 | 0.82 | CA2 (0.37) | ALDH1A1LMNA | |
| SCHEMBL28067322 | 0.80 | CTSS (0.34) | RAB9A | |
| SCHEMBL1068440 | 0.80 | HSD11B1 (0.33) | MAOBALDH1A1IDO1 | |
| SCHEMBL22729269 | 0.79 | TRPA1 (0.35) | IDO1 | |
| SCHEMBL8115470 | 0.79 | KDM4E (0.38) | KMT2AMAOBIDO1 | |
| SCHEMBL1067751 | 0.77 | SLC22A12 (0.36) | IDO1 | |
| SCHEMBL8125091 | 0.77 | BACE1 (0.36) | GAAMAOBALDH1A1LMNA | |
| SCHEMBL4544271 | 0.76 | LTA4H (0.38) | MAOBALDH1A1IDO1MAPTRAB9A | |
| SCHEMBL12816738 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| EP-2176256-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | claimed |
| WO-2009007751-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | claimed |
| US-20240016152-A1 | ACTIVE COMPOUND COMBINATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-18 | — | — | US | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230064576-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20230054449-A1 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-23 | — | — | US | disclosed |
| EP-4116303-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER | Loxo Oncology, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-0243173-B1 | NEW DIPHOSPHONIC ACID COMPOUNDS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-06-26 | — | — | EP | disclosed |
| US-4963536-A | INHIBIT BONE RESORPTION | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-10-16 | — | — | US | disclosed |
| US-4857513-A | Diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISIWA PHARMACEUTICAL CO., LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0243173-A2 | New diphosphonic acid compounds, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-28 | — | — | EP | disclosed |
| US-4225608-A | ANTIDEPRESSANTS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1980-09-30 | — | — | US | disclosed |
| EP-0004288-A2 | Phenoxyalkyl amines, pharmaceutical compositions containing them, and process for their preparation | MERCK PATENT GmbH (DE) | 1979-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016152-A1 | ACTIVE COMPOUND COMBINATIONS | CYP51A1, ERG28, BROX | KMT2A 1871/4885GAA 231/4885NFE2L2 2054/4885 |
| US-20230064576-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | PNPO, PDXK, BLVRB | KMT2A 2293/4885GAA 695/4885NFE2L2 2769/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | KMT2A 1615/4885GAA 624/4885NFE2L2 1328/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | KMT2A 908/4885GAA 456/4885NFE2L2 1282/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | KMT2A 1615/4885GAA 624/4885NFE2L2 1328/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | KMT2A 908/4885GAA 456/4885NFE2L2 1282/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | KMT2A 908/4885GAA 456/4885NFE2L2 1282/4885 |
| US-20230054449-A1 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | PNPO, TPMT, BLVRB | KMT2A 1161/4885GAA 941/4885NFE2L2 3364/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | KMT2A 1615/4885GAA 624/4885NFE2L2 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.